According to the research report titled ‘Asia Pacific Electrophysiology Market Size By Product, By Indication, By End-use, Industry Analysis Report, Regional Outlook, Application Potential, Competitive Market Share & Forecast, 2021 – 2027’, available with Market Study Report, Asia-Pacific electrophysiology market is likely to exceed a valuation of USD 2.5 billion by the year 2027.
 

Increased pervasiveness of cardiovascular diseases such as tachycardia, atrial flutter, and atrial fibrillation coupled with innovative product launches are some of the key factors positively influencing Asia-Pacific electrophysiology market.
 

Request sample copy of this Report: https://www.marketstudyreport.com/request-a-sample/3212726/
 

Additional factors such as growing elderly population, widespread adoption of sedentary lifestyle, increasing number of electrophysiology treatment options and high patient pool are fueling the market size. Improving cognizance regarding catheter ablation procedure, technological advancements in this business domain and integration of robotics solutions are favoring Asia-Pacific electrophysiology industry outlook.
 

On the contrary, lack of skilled medical staff and high costs of electrophysiology devices could hinder the market expansion. The ongoing COVID-19 pandemic has also had a severe impact on the remuneration scale of this market space, with several elective procedures being postponed in order to prioritize treating patients with Coronavirus.
 

Regardless, declining number of COVID-19 cases owing to vaccine roll outs coupled with recovering economic conditions are likely to provide lucrative growth opportunities for the industry participants in the forthcoming years.
 

Based on product landscape, the report states that EP diagnostic catheters segment accounted for 35% market share in the year 2020, owing to their widespread usage for detecting atrial fibrillation as well as to determine most appropriate treatment option. Rising prevalence of obesity and increasing geriatric population are also fueling the segmental size.
 

By indication, atrial tachycardia segment generated USD 25 million for Asia-Pacific electrophysiology industry in 2020. High occurrence of atrial tachycardia owing to increasing drugs & alcohol consumption in tandem with rising number of electrophysiology procedures are favoring the overall market scenario.
 

Citing the end-user spectrum, the report cites that Asia-Pacific electrophysiology industry share from catheterization laboratories/EP laboratories segment is predicted to expand with a CAGR of 14% between 2021 and 2027. Electrophysiology is known to offer various technologically advanced products. In addition, alarming increase in cardiac arrythmias and growing number of skilled professionals is adding traction to the overall market size.
 

Considering the geographical landscape, India electrophysiology market is reckoned to witness a y-o-y growth rate of 13% through 2027. Improving healthcare infrastructure, rising adoption of advanced electrophysiology devices, and favorable regulatory outlook are facilitating the business scenario in India.
 

The competitive landscape of Asia-Pacific electrophysiology market is defined by companies such as Topera Inc., Stereotaxis Inc., Siemens AG, Magnetecs Corporation, MicroPort Scientific Corporation, Medtronic plc, Koninklijke Philips N.V., Johnson & Johnson, Japan Lifeline Co. Ltd., GE Healthcare, Boston Scientific Corporation, Biotronik SE & Co. KG, and Abbott Laboratories among others.